Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LMT stock price vs AMGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMGN's multiple
Needs AMGN P/E.
Implied fair value · at LMT's multiple
Needs LMT P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
LOCKHEED MARTIN CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Amgen Inc. · implied price per share
Bear
$98.66
Base
$130.87
Bull
$172.82
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BOEING CO
LMT vs BA
NORTHROP GRUMMAN CORP /DE/
LMT vs NOC
TEXTRON INC
LMT vs TXT
HUNTINGTON INGALLS INDUSTRIES, INC.
LMT vs HII
AXON ENTERPRISE, INC.
LMT vs AXON
Howmet Aerospace Inc.
LMT vs HWM
REGENERON PHARMACEUTICALS, INC.
LMT vs REGN
BIOGEN INC.
LMT vs BIIB
VERTEX PHARMACEUTICALS INC / MA
LMT vs VRTX
Gilead Sciences, Inc.
LMT vs GILD
Moderna, Inc.
LMT vs MRNA
Eli Lilly and Company
LMT vs LLY
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LMT can sustain its current earnings multiple while improving margins or growth from current levels, then a modestly constructive stance is justified because the stock is about 5.6% below the P/E-implied price and trades below AMGN on P/E; otherwise, the weaker margin and growth profile argues for patience rather than aggressive buying.
At the current price of $587.95, LMT is trading below the P/E-derived implied price of $620.60, suggesting about 5.6% upside. However, AMGN comparison is not a simple discount story because LMT also trades at a much lower P/S multiple than AMGN, while profitability and growth remain meaningfully weaker.
Supporting Metrics
